A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis

ClinicalTrials.gov ID: NCT02576717

Public ClinicalTrials.gov record NCT02576717. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis.

Study identification

NCT ID: NCT02576717
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Celgene; Industry
Enrollment: 2,494 participants

Conditions and interventions

Conditions

Multiple Sclerosis

Interventions

RPC1063 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 55 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 16, 2015 (Actual)
Primary completion: Jan 5, 2023 (Actual)
Completion: Jan 5, 2023 (Actual)
Last update posted: Jan 30, 2024

2015 – 2023

United States locations

U.S. sites: 19
U.S. states: 10
U.S. cities: 18

Facility	City	State	ZIP	Site status
Local Institution - 115	Phoenix	Arizona	85004	—
Local Institution - 118	Phoenix	Arizona	85013	—
Local Institution - 110	Berkeley	California	94705	—
Local Institution - 103	Fresno	California	93710	—
Local Institution - 122	Long Beach	California	90806	—
Local Institution - 112	Sacramento	California	95817	—
Local Institution - 120	San Francisco	California	94158	—
Local Institution - 114	Maitland	Florida	32751	—
Local Institution - 123	Port Charlotte	Florida	33952	—
Local Institution - 124	Sunrise	Florida	33351	—
Local Institution - 147	Tampa	Florida	33609	—
Local Institution - 137	Golden Valley	Minnesota	55422	—
Local Institution - 170	Las Vegas	Nevada	89106	—
Local Institution - 143	Raleigh	North Carolina	27607	—
Local Institution - 107	Westerville	Ohio	43801	—
Local Institution - 144	Knoxville	Tennessee	37922	—
Local Institution - 138	Lubbock	Texas	79410	—
Local Institution - 179	Round Rock	Texas	78681	—
Local Institution - 141	Kirkland	Washington	98034	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 156 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02576717, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 30, 2024 · Synced Oct 19, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02576717 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →